Acepodia obtained FDA IND clearance for ACE-723, a GPC3-targeted dual-payload antibody-drug conjugate aimed at unresectable or metastatic hepatocellular carcinoma. The company plans to begin a Phase I trial to evaluate safety and clinical activity. The development underscores ongoing investment in liver cancer ADCs that use GPC3 as a tumor-selective entry point while leveraging a dual-payload design to increase potency. The Phase I start date and early expansion cohorts will be watched as indicators of whether the next-generation ADC architecture translates clinically. With Acepodia joining other companies in the dataset advancing ADCs through early clinical stages, the competitive landscape for solid-tumor conjugates remains active. The near-term impact is mostly clinical development momentum for a differentiated liver cancer targeting approach.